It accumulates over years. It lives in the gap between what you know and how you know when to apply it. It is called judgment — and for the entirety of human history, it has been the most valuable and the most perishable thing we produce.
I have spent twenty years in medtech. I have sat in rooms with people who carry something irreplaceable — the kind of understanding that cannot be transmitted in a slide deck, cannot be compressed into a training module, and does not transfer when someone walks out the door for the last time.
The problem with our industry is not a shortage of information. We have more data than we know what to do with. Reimbursement tables. Regulatory pathways. Clinical evidence. All of it is searchable. None of it is judgment.
"What happens to everything you know when you're no longer in the room?"
Every year, senior clinicians retire. Principal investigators move on. Regulatory strategists who carried a company through its first 510(k) go quiet. The institutional memory they held — the memory of how to navigate FDA's unwritten norms, how to read the room in a payer meeting, how to spot the product-market fit no one else could see — that memory disappears with them.
We talk about knowledge management. We build wikis. We conduct exit interviews. We archive decks. And then someone new joins the company, faces the same inflection point, and there is no one to call who actually knows.
The loss is not the data. The loss is the judgment. The accumulated sense of how to act when the playbook runs out. That is what disappears, and that is what we have never had a way to preserve.
I do not believe this is inevitable. I believe we are at the beginning of a period when the texture of human expertise — not just its outputs, but its reasoning, its intuition, its hard-won pattern recognition — can be encoded in a way that outlasts any single career.
Not as a knowledge base. Not as a chatbot trained on documents. But as something closer to a living extension of the person themselves — an AI twin that responds the way they would respond, caveats what they would caveat, pushes back where they would push back.
That is the work I am committed to. It is not a product feature. It is a belief about what this technology is actually for.
The medtech founders who find their way to NathanTwin are not looking for another search engine. They are looking for someone who has been in the room — with the FDA reviewer, with the payer committee, with the surgeon who wouldn't commit until the data was airtight — and can help them navigate their own version of that moment.
What they are really looking for is judgment on demand. And that is what is becoming possible.
The Circle is a membership for senior medtech professionals — medical directors, regulatory veterans, commercialization leads — who are ready to encode their judgment as an AI twin. Twenty founding seats. One field. A permanent record of how it was actually done.